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EpCAM is highly overexpressed on most carcinoma types and serves as a marker for diagnosis
and as an immunotarget for clinical trials.1 For some carcinoma types, EpCAM overexpression has
been associated with poor clinical outcome, suggesting that downregulation of EpCAM expression
provides a promising approach to interfere with oncogenic potential of the tumor cells. The studies
described in this thesis aim to selectively target and downregulate EpCAM by epigenetic editing.
Epigenetic editing provides a novel approach to overwrite molecular epigenetic marks by an
epigenetic eector domain targeted to specic genes by a sequence specic DNA-binding motif.
Towards this end, we characterized the (epi)genetic regulation of the gene that codes for the EpCAM
protein and designed a novel approach to downregulate EpCAM expression in a permanent way.
Biological role of EpCAM in cancer
In Chapter 2, we summarize current literature regarding the (epi)genetic regulation of the EpCAM
gene itself, and we review the biological role of EpCAM in carcinogenesis, tumor progression and
metastasis in a broad range of carcinoma types. The role of EpCAM in development of cancer and
tumor progression appears to be paradoxical. For example, in breast cancer high EpCAM expression
correlates with poor prognosis2 and downregulation of EpCAM has been shown to decrease the
oncogenic potential.3 In contrast, high EpCAM expression in primary renal cell carcinomas is
associated with improved patient survival.4;5 In other types of carcinoma like ovarian cancer, the
role of EpCAM is not clear and contradictory results have been reported. In one study, FIGO stage III/
IV showed lower EpCAM expression than stage I6, while in another study, FIGO stage III/IV showed
higher EpCAM expression than stage I/II disease.7 The latter study suggests that a higher expression
of EpCAM correlates with tumor progression, although no correlation with survival was found.7
However, a more recent study reported that EpCAM overexpression was signicantly related to a
decreased overall survival of patients with epithelial ovarian cancer.8 Importantly, metastatic and
recurrent tumors were found to express signicantly higher levels of EpCAM protein when compared
with primary ovarian carcinomas.9 Despite the seemingly contradictory results, these observations
suggest rather a promoting than a protecting role for EpCAM in ovarian cancer.
To reveal more insights in this apparently paradoxical role of EpCAM in ovarian cancer, we eectively
downregulated EpCAM expression of ovarian cancer cell lines by siRNA and performed migration
assays. EpCAM siRNA treatment resulted in almost 90% decrease in EpCAM expression compared
with irrelevant siRNA (Figure 1, left). EpCAM siRNA treatment resulted in a reduced migration
potential compared to cells treated with irrelevant siRNA as shown in Figure 1 (right). However,
this reduced migration eect was not consistently shown in independent migrations assays, nor in
dierent ovarian cancer cell lines.
Similarly, proliferation or scratch assays showed no signicant dierence in oncogenic potential
between ovarian cancer cell lines treated with EpCAM siRNA or irrelevant siRNA. To validate our
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assays, we included a breast cancer cell line for which others had shown a decrease in invasion and
migration potential after siRNA-mediated downregulation of EpCAM.3 However, despite an eective
downregulation of EpCAM expression, we could not conrm their results. Further studies need to be
conducted (identifying suitable irrelevant siRNA; optimizing read out systems) before a conclusion
can be drawn on the role of EpCAM in ovarian cancer. So far, for ve dierent carcinoma cell lines
(head and neck10, gastric11, hepatocellular12, tongue squamous cell carcinoma13 and breast cancer3)
transient downregulation of EpCAM expression reduced the oncogenic potential, indicating a
powerful role of EpCAM at least in some carcinoma types. For ovarian cancer, the frequent observed
EpCAM overexpression might be the eect of dysregulated transcription factors. We therefore
investigated in Chapter 3 whether transcription factors described to play a potential role in ovarian
cancer, are associated with the EpCAM gene in living cells.
Transcription factors in ovarian cancer
It has been suggested that the ß-catenin/TCF/LEF pathway might be an important factor in the
development of ovarian cancer.14 Nuclear localization of β-catenin in the high-grade serous
carcinomas was shown to be signicantly higher than in the low-grade carcinoma group15,
indicating that one of the mechanisms for carcinogenesis in high-grade serous epithelial ovarian
cancer might be through the activation of the LEF/β-catenin pathway.14 Activity of ß-catenin/
TCF complex is essential for the transcription of genes that direct proliferation of tumor cells. In
a hepatocellular carcinoma cell line it has been shown that EpCAM is induced upon activation of
β-catenin.16 Moreover, upon proteolytic cleavage of EpCAM’s extracellular domain, the intracellular
part of EpCAM forms a nuclear complex containing LEF-1/β-catenin which upregulates the oncogen
c-myc and cyclin A and E.17 In turn, the extracellular domain of EpCAM can function as a ligand
in EpCAM signaling. In EpCAM positive ovarian cancer cell lines, we indeed found association of
Figure 1. Migration assay performed with OVCAR3 cells after e!ectively siRNA mediated downregulation
of EpCAM expression. Cells were transfected with EpCAM specic siRNA or irrelevant siRNA. After 72h, part
of the cells was harvested for EpCAM expression by "ow cytometry (left). The rest of the cells were used for























































LEF-1 with the EpCAM promoter, indicating that LEF-1 might play a potential role in the EpCAM
overexpression observed in ovarian cancer.
Other examples of transcription factors playing an important role in ovarian cancer are the
proliferation promoting E2F2 and the inhibiting E2F4 transcription factors. High mRNA levels of
E2F2 and low levels of E2F4 compared to levels in normal tissue are signicantly associated with a
poor survival.18 Interestingly, a low E2F2 to E2F4 ratio appears to be the most powerful prognostic
marker for disease free-survival.18 In the EpCAM positive ovarian cancer cell lines, we found both
E2F2 and E2F4 to be associated with the EpCAM promoter. In view of this, it is of great interest to
investigate the inuence of these transcription factors on EpCAM expression. Especially, since it has
been shown that methylation of CpGs of some promoters within the binding motif of E2F2 and E2F4
eectively blocks the binding of the transcription factors.19 Since we indeed found only association
of these transcription factors with the hypomethylated EpCAM promoter, we propose a direct role
for E2F2 and E2F4 in EpCAM regulation.
Epigenetic marks and EpCAM expression
The accessibility of transcription factors to the DNA is dictated by the chromatin structure which is
dependent on among others DNA methylation and histone modications. Since EpCAM is highly
overexpressed in all subtypes of ovarian cancer, loss of DNA methylation might also be one of the
underlying mechanisms in this carcinoma type. For patient samples of lung adenocarcinoma20,
colon21 and oral squamous cell carcinoma22, high EpCAM expression has been shown to correlate
with a hypomethylated EpCAM promoter. In Chapter 3 we show that in a panel of ovarian cancer
cell lines EpCAM expression indeed correlated inversely with DNA methylation. Interestingly, gel
retarding assays with a nuclear extract and a probe containing a putative binding site for Sp1,
showed inhibition of binding when the CpG within this binding site is methylated. Moreover, the
CpG located in this putative binding site was methylated in EpCAM negative ovarian cancer cell
lines and never methylated in EpCAM positive cells. We conrmed that association of Sp1 with the
endogenous EpCAM promoter was restricted to EpCAM positive cells. Since it has been shown that
the presence of Sp1 increases promoter activity20, it is plausible that methylation of the promoter
impairs the activation by Sp1. This nding is of great importance in view of our aim to downregulate
EpCAM gene expression, since it gives an indication to which location in the promoter one should
target to achieve e!cient downregulation of EpCAM expression.
In addition, we found general active histone modications to be associated with an active
promoter, whereas a silent promoter was associated with repressive marks. Interestingly, recently
it has been reported that during dierentiation of human embryonic stem cells EpCAM expression
is not silenced by DNA methylation but by reduction of active histone marks and an enhancement
of repressive marks.23 However, in our panel of ovarian cancer cell lines we found both epigenetic
marks DNA hypermethylation as well as repressive histone marks to be associated with no EpCAM
expression. The combination of DNA hypermethylation of the promoter in EpCAM negative cells
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with the association of repressive histone marks may account for the fact that we did not detect any
transcription factors to be associated with the EpCAM promoter. Hypermethylated DNA associated
with trimethylated lysines 9 or 27 of histone 3, induces a closed chromatin structure which hinders
the accessibility for transcription factors.
Delivery of DNA methyltransferase
Modulation of EpCAM expression on epigenetic level implies that epigenetic modi!ers i.e. DNA
methyltransferase and/or histone modi!ers have to be delivered into the cells. Although DNA
and siRNA can be e"ciently delivered into cells, no agent was available to deliver proteins in the
presence of serum. The advantage of protein delivery over DNA delivery is that the former does not
require transcription by the host cell into a biologically active protein. In this way, the dose of protein
to be delivered is easier to control. In addition, to achieve targeting of epigenetic modi!ers to the
EpCAM gene, the enzyme needs to be coupled to a sequence speci!c synthetic DNA-binding motif.
In Chapter 4 we show that the cationic liposome SAINT-2:DOPE is an excellent protein delivery agent.
Labeling studies demonstrated e"cient delivery for protein (called profection) as well as for DNA
and siRNA. Delivered proteins were still able to exert their function as shown by β-galactosidase
activity and the general applicability was shown by the delivery of this enzyme into adherent or
non-adherent cell lines, as well as into di"cult to transfect primary cells. Of great importance for in
vivo delivery, profection with SAINT-2:DOPE was not signi!cantly a$ected by the presence of serum.
Since epigenetic modi!ers need to enter the nucleus to exert their function, we delivered the
DNA methyltransferase M.SssI and measured its e"ciency in DNA methylation. The E-cadherin
gene was used as a model gene, as the expression of this gene is known to be responsive to DNA
methylation silencing.24 Nuclear activity of delivered M.SssI was established by the observed elevated
methylation status of the E-cadherin gene and con!rmed by reduced E-cadherin expression.
Because M.SssI e"ciently methylates CpGs and acts genome wide, the enzyme is toxic to the
cells. Therefore, M.SssI delivery speci!c to the tumors cells would be an alternative approach to
eliminate tumor cells. Because of its high expression on a broad range of tumor types, EpCAM can be
used as a target antigen to deliver M.SssI speci!c to the tumor cells. The advantage of this approach
compared to currently ongoing immunotherapeutic clinical trials is that once the M.SssI is delivered
into the tumor cells, the cells will be directly killed instead of being dependent on the recruitment
of immune cells to induce elimination of the tumor cells. To this extend, an antibody speci!c for
EpCAM can be coupled to the delivery agent SAINT-2:DOPE which can direct M.SssI speci!c to the
tumor cells. Indeed, an anti-EpCAM Fab’-fragment coupled to liposomes showed more e"cient
delivery of the conjugated enzyme to tumor cells than the corresponding anti-EpCAM-enzyme
conjugate.25 Also for SAINT-2:DOPE, conjugation of an anti-E-selectin antibody e"ciently increased
the siRNA uptake speci!c into activated endothelial cells expressing E-selectin compared to resting
cells, which are E-selectin negative.26 Although, EpCAM is also expressed on healthy epithelia, the




to the leaky vasculature of tumors, allows the therapeutic compound to preferentially localize in the
tumor. This idea was conrmed in a study in transgenic mice in which EpCAM on tumor cells was
much more accessible to antibodies than EpCAM expressed in normal tissues.27
Epigenetic downregulation of EpCAM expression
In Chapter 5 we explored whether active interfering with the DNA methylation status of the
promoter indeed resulted in changes in EpCAM gene expression. Treatment of EpCAM negative cells
with a DNA methylation inhibitor induced de novo EpCAM expression, both on mRNA and protein
level, and caused upregulation of EpCAM expression in a moderately EpCAM expressing ovarian
cancer cell line. Upon delivery of M.SssI, an elevated DNA methylation level of the EpCAM promoter
was observed, which correlated with an e!ciently reduced EpCAM expression. While siRNA-
mediated downregulation remained for 4 days, after which EpCAM re-expression increased in time,
M.SssI-mediated downregulation remained through successive cell divisions as the reduced EpCAM
expression persisted for at least 17 days, illustrating the transferable e"ect of epigenetic modulation.
Compared to siRNA-mediated downregulation, the M.SssI induced EpCAM reduction was initially
less e!cient, but delivery of M.SssI is dose limiting because of toxicity. Although the elevated DNA
methylation of the promoter suggests a direct e"ect of M.SssI on EpCAM expression, the genome
wide methylation by M.SssI will silence many genes. Hence, the reduced EpCAM expression could
be the indirect result of for example silencing of endogenous miRNA181s. Inhibition of endogenous
miRNA-181s has been shown to reduce EpCAM mRNA levels28 and epigenetic control of miRNA
expression has been reported.29 To demonstrate that DNA methylation of the EpCAM promoter
directly a"ects the EpCAM expression, and to increase the DNA methylation e!ciency of the EpCAM
promoter, targeting of the enzyme to the EpCAM promoter is required.
EpCAM speci!c downregulation by DNA methylation
In Chapter 6, we are the rst to demonstrate that the conjugation of a TFO with a DNA
methyltransferase is able to target methylation predominantly to the target CpG without
any background methylation. The advantage of using a mutant methyltransferase with less
methyltransferase activity is that the targeting is dominated by the TFO and not by the enzyme.
Treatment with the TFO-C141S conjugate caused relaxation of the plasmid, most likely due to
topoisomerase activity reported for M.SssI.30 However, the observed topoisomerase activity was only
displayed by the TFO-C141S conjugate and not by the TFO or C141S only. Somehow, the chemical
coupling of the TFO with the enzyme seems to change the conformation of the enzyme, thereby
uncovering the catalytic topoisomerase domain. The enzyme activity should be easy to abolish by
replacing an amino acid in the active site of the isomerase domain. Since, M.SssI contains a tyrosine
in a similar amino acid context to the catalytic tyrosine of other characterized topoisomerases,
tyrosine 137 might be the most promising candidate.30 Once this is successful, the mutated DNA
methyltransferase C141S is generally applicable, because in this variant the internal cysteines are
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replaced and the introduced C-terminal Cys allows coupling of the methyltransferase to any TFO.
However, the topoisomerase activity displayed by our TFO-C141S may cause no problem in
living cells, because the topoisomerase will reconnect the DNA again. Transfection of the TFO-C141S
with the delivery agent SAINT-2:DOPE in EpCAM positive ovarian cancer cells showed in our hands,
no eect on EpCAM expression. To improve the biological eect of targeted methylation by TFO-
C141S on endogenous EpCAM gene expression, additional considerations should be taken into
account. Under physiologic conditions, the TFO needs to be nuclease resistant and the pyrimidine-
rich TFO used in our study requires protonation of cytosines at N3 to form proper Hoogsteen
bonds.31 Progress in TFO-technology allows solving of both limitations by chemical modications.
For example, substitution of cytosine with 5-methyl-2’-deoxycytidine increases protonation as
5-methyl-C has a higher pK than does cytosine and resistance to 3’-end nucleases can be increased
by addition of a propanediol tail. TFOs have been used to target cleavage, cross-linking or anticancer
agents to various genes resulting in inhibition of gene expression31, illustrating that modied TFOs
are suitable tools as targeting domains in living cells.
Transfection of the TFO-C141S treated reporter plasmid in the presence or absence of a methyl
donor showed no eect on EpCAM promoter activity caused by methylation of a single CpG. The
absence of silencing could be explained by 1) methylation of one single CpG is not enough to
induce silencing of the promoter or 2) the targeted CpG is located in a region which is not important
for regulation. If the targeted CpG is located in a binding site for a transcription factor important
for activation of EpCAM gene transcription, and this binding is DNA methylation sensitive like we
found for Sp1, methylation of this particular CpG might have a direct eect on gene expression.
Alternatively, methylation of just a single CpG may recruit repressor proteins like heterochromatin
protein 1, histone methyltransferases, deacetylases and DNA methyltransferase DNMT1, DNMT3a
and 3b and induce DNA methylation spreading. Transfection of a reporter plasmid under control of
the p53 promoter in which a single CpG was methylated in vitro by HhaI, showed 85% downregulation
of the reporter gene.32 Restriction analysis with methylation sensitive enzymes performed on
the plasmids 48h after transfection, revealed indeed methylation of additional CpGs. These data
demonstrate that a single CpG could trigger subsequent spreading of methylation to other CpG
sites. In addition, the location of the targeted CpG seems to be of great importance in epigenetic
modulation, because methylation of a single CpG at another location by FnuDII methylase in the
p53 promoter was not associated with promoter suppression and methylation spreading.32
Apart from the number of CpGs that has to be methylated to induce gene silencing, the acquired
insights regarding the DNA methylation status of the EpCAM promoter in correlation with EpCAM
expression suggest that one should target to another region in the EpCAM promoter than the target
CpG of our TFO-C141S. Since the DNA methylation level in the area upstream of the transcription
starting site (-443 to -130) showed an increase correlating with a decrease in EpCAM expression
(Chapter 3) this might be the most promising region to initiate eective downregulation of EpCAM




region. However, this region is CG rich which makes it more dicult to design a TFO with a high
anity. An alternative targeting moiety might be deduced from zinc ngers. Trimeric and hexameric
zinc ngers, designed to target the region (-171 to -130) and fused to a repressor or an activation
domain, have been shown to modulate EpCAM promoter activity.33 DNA methyltransferases
genetically fused to zinc nger proteins have been shown to eciently repress reporter gene
expression.34 Interestingly, mouse DNMT3a or DNMT3b DNA methyltransferases fused to DNA
binding domains induced dense methylation of DNA regions comprising up to 380 bp on both sites
of the specic DNA binding site.35 This nding suggests that initial methylation with mammalian
DNA methyltransferases might serve as trigger for DNA methylation spreading as described above.
Moreover, a mutant DNA methyltransferase fused to zinc nger proteins has been shown to induce
targeting methylation leading to gene silencing via initiation of a repressive chromatin signature at
the targeted genomic locus.36
An alternative way to induce targeted methylation is via short interference (si)RNA targeting
promoters.37 In Chapter 7 we report on a siRNA designed to target mRNA molecules inducing
sustained silencing in a subset of cells, which correlated with an elevated DNA methylation level
of the promoter. This observation was unexpected as the aim of this study was to demonstrate the
advantages of the permanent silencing via inheritable DNA methylation compared to the siRNA-
mediated transient silencing. As mRNA molecules are constantly produced, RNA-based approaches
require repeated administration of the inactivating reagent. In contrast, a single administration
of a DNA methyltransferase is expected to be sucient to silence, because the maintenance DNA
methyltransferases in the cell will copy the new methylation mark in the absence of the exogenous
methyltransferase. In addition, targeted DNA methylation needs to a!ect just two copies of the
EpCAM gene rather than the numerous copies of mRNA present in each cell. Since M.SssI induced
downregulation of EpCAM expression in a subpopulation of cells, we sorted and cultured this
subpopulation to demonstrate that the downregulation of EpCAM expression was indeed enduring
and correlated with an elevated methylation level of the EpCAM promoter. In this experimental
setting the siRNA treated cells functioned as a control. Unexpectedly, after two rounds of selection
for weak EpCAM expressing cells, we found a small percentage of the initially siRNA treated cells
with a permanently reduced EpCAM expression also correlating with an elevated DNA methylation
level. Speculating on this interesting nding, it appears that in a small percentage of cells the siRNA
is transfected into the nucleus by SAINT-2:DOPE, hereafter spreading of DNA methylation causes the
permanent downregulation. To proof the occurrence of methylation spreading, DNA methylation
analysis of the siRNA targeting region should be analyzed rst, followed by the possible recruitment
of repressive histone modications. To exclude the selection of cells with a ”spontaneous” high
DNA methylation, two rounds of selection and culturing of weak EpCAM expressing cells out of
the untreated cell line, did not result in a subpopulation of cells with a higher DNA methylation
level than unsorted cells. However, to validate our nding, the appropriate control is to repeat the
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experiment and include a single transfection with irrelevant siRNA.
Future perspectives
E!ective and speci"c delivery of the EpCAM gene speci"c epigenetic modi"er in vivo to minimize
possible side e!ects is the most challenging remaining hurdle. Combination of a tumor targeted
delivery system with a gene speci"c epigenetic modi"er is expected to increase the speci"city.
This double targeted system consists of an EpCAM speci"c antibody coupled to the delivery agent
SAINT-2:DOPE which can direct the EpCAM speci"c TFO-C141S or siRNA speci"c to the tumor cells
(Figure 2).
Figure 2. Proposed model of double targeting to tumor cells by using the EpCAM protein on the surface















Carcinoma cell with nucleus
An alternative approach to prevent methylation of nontargeted sites is the so called split DNA
methyltransferase strategy as proposed by Kiss and Weinhold.38 This approach is based on splitting
naturally monomeric methyltransferases into two fragments and fusing the fragments to di!erent
DNA bindingdomains like zinc "nger proteins that bind DNA #anking the target site for methylation.
When both fusion products are expressed in the same cell an active methyltransferase is formed
that can only methylate the target site. Delivery of this double targeting device by EpCAM-SAINT-
2:DOPE is expected to silence the overexpressed EpCAM gene only in the EpCAM positive tumor




In conclusion, the work presented in this thesis revealed more insights in the regulation of the
EpCAM gene. We explored three novel approaches to downregulate EpCAM expression in a
permanent way via DNA methylation. Firstly, nuclear protein delivery of M.SssI resulted in an
elevated DNA methylation level of the EpCAM promoter inducing a persistent downregulation of
EpCAM expression. However, untargeted M.SssI can methylate the whole genome and is therefore
toxic. Secondly, we report on a siRNA designed to target EpCAM mRNA molecules which induced
a sustained downregulation of EpCAM expression in a subpopulation of cells, correlating with
an elevated DNA methylation of the EpCAM promoter. Although this new nding might expand
the range of potential clinical siRNA applications, this might not be an easy applicable strategy.
Targeted DNA methylation by our TFO-C141S conjugate provides a exible tool: by the use of
TFOs as targeting domain, and the wide applicability of the mutated DNA methyltransferase, this
approach appears to be a promising tool in both research and therapeutic areas.
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